Free Trial
→ How to claim a stake in SpaceX before the June 12 IPO (From Brownstone Research) (Ad)tc pixel Free IMVT Stock Alerts

Immunovant (IMVT) Earnings Date, Estimates & Call Transcripts

Immunovant logo
$33.41 -0.42 (-1.24%)
Closing price 05/27/2026 04:00 PM Eastern
Extended Trading
$32.88 -0.53 (-1.59%)
As of 04:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Immunovant Earnings Summary

Immunovant announced Q4 2026 earnings on May 20, 2026, reporting an EPS of -$0.73, which missed the consensus estimate of -$0.60 by $0.13. With a trailing EPS of -$2.78, Immunovant's earnings are expected to grow next year, from ($2.62) to ($2.56) per share.

Upcoming Q1
Earnings Date
Aug. 10Before Market OpensEstimated
Consensus EPS
(May. 20)
-$0.60
Actual EPS
(May. 20)
-$0.73 Missed By -$0.13

Q4 2026 Earnings Resources

IMVT Upcoming Earnings

Immunovant's next earnings date is estimated for Monday, August 10, 2026, based on past reporting schedules.

Powered by Quartr
Get Immunovant Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunovant and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

IMVT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Immunovant Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20262-$0.82-$0.62-$0.72
Q2 20264-$0.87-$0.70-$0.77
Q3 20264-$0.83-$0.70-$0.75
Q4 20264-$0.73-$0.61-$0.69
FY 2026 14 -$3.25 -$2.63 -$2.93
Q1 20272-$0.87-$0.69-$0.78
Q2 20272-$0.89-$0.70-$0.80
Q3 20272-$0.89-$0.62-$0.76
Q4 20272-$0.67-$0.66-$0.67
FY 2027 8 -$3.32 -$2.67 -$3.00
Q1 20281-$0.73-$0.73-$0.73
Q2 20281-$0.70-$0.70-$0.70

Immunovant Earnings History by Quarter

Export
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/10/2026
(Estimated)		--------
5/20/2026Q4 2026-$0.60-$0.73 -$0.13-$0.73--
2/6/2026Q3 2026-$0.72-$0.61+$0.11-$0.61--
11/10/2025Q2 2026-$0.72-$0.73 -$0.01-$0.73--
8/11/2025Q1 2026-$0.69-$0.60+$0.09-$0.71--
5/29/2025Q4 2025-$0.72-$0.64+$0.08-$0.64-$0.16M
2/10/2025Q3 2025-$0.68-$0.76 -$0.08-$0.76--
11/7/2024Q2 2025-$0.59-$0.74 -$0.15-$0.74--
8/6/2024Q1 2025-$0.53-$0.60 -$0.07-$0.60--
5/29/2024Q4 2024-$0.44-$0.52 -$0.08-$0.52--

Data powered by Fiscal.ai.

Immunovant Earnings - Frequently Asked Questions

Immunovant has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 10th, 2026 based off last year's report dates. Learn more on IMVT's earnings history.

In the previous quarter, Immunovant (NASDAQ:IMVT) missed the analysts' consensus estimate of ($0.60) by $0.13 with a reported earnings per share (EPS) of ($0.73). Learn more on analysts' earnings estimate vs. IMVT's actual earnings.

The conference call for Immunovant's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Immunovant's latest earnings report can be read online.
Read Transcript

Immunovant's earnings report can be found in their filing with the SEC.
View SEC filing

Immunovant (NASDAQ:IMVT) has a recorded net income of -$505.61 million. IMVT has generated -$2.78 earnings per share over the last four quarters.

Immunovant's earnings are expected to grow from ($2.62) per share to ($2.56) per share in the next year.

Related Companies
Earnings Tools

This page (NASDAQ:IMVT) was last updated on 5/28/2026 by MarketBeat.com Staff.
From Our Partners
How to claim a stake in SpaceX before the June 12 IPO
SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...
Brownstone Research | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX hype is real. So is what happens after.
SpaceX just filed for what could be a $2 trillion IPO, with the roadshow starting in June. History shows that ...
Americas Gold Company | Sponsoredtc pixel
Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever
"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...
Behind the Markets | Sponsoredtc pixel
A 25,000% opportunity
Angel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...
The Oxford Club | Sponsoredtc pixel